Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week. Moderna recently developed a new flu vaccine using the same mRNA technique that underpins its COVID-19 vaccine. But after requesting review from the federal government, the FDA initially declined to review the drug — a necessary regulatory step toward bringing the drug to market — saying ...